{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:10:07Z","timestamp":1780063807031,"version":"3.54.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ferring Pharmaceuticals, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-026-02158-x","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:39:12Z","timestamp":1780061952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety evaluation of a novel progesterone vaginal ring (PVR) for luteal phase support: SARA trial"],"prefix":"10.1007","author":[{"given":"Laurel A.","family":"Stadtmauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki L.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristin C.","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Heiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"3","key":"2158_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41574-023-00921-5","volume":"20","author":"A Garg","year":"2024","unstructured":"Garg A, Zielinska AP, Yeung AC, et al. Luteal phase support in assisted reproductive technology. Nat Rev Endocrinol. 2024;20(3):149\u201367. https:\/\/doi.org\/10.1038\/s41574-023-00921-5.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2158_CR2","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1055\/s-0035-1545363","volume":"33","author":"EH Yanushpolsky","year":"2015","unstructured":"Yanushpolsky EH. Luteal phase support in in vitro fertilization. Semin Reprod Med. 2015;33(2):118\u201327. https:\/\/doi.org\/10.1055\/s-0035-1545363.","journal-title":"Semin Reprod Med"},{"issue":"7","key":"2158_CR3","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.fertnstert.2010.02.033","volume":"94","author":"E Yanushpolsky","year":"2010","unstructured":"Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein M. Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertil Steril. 2010;94(7):2596\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.02.033.","journal-title":"Fertil Steril"},{"key":"2158_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1742-4755-11-78","volume":"11","author":"AN Beltsos","year":"2014","unstructured":"Beltsos AN, Sanchez MD, Doody KJ, Bush MR, Domar AD, Collins MG. Patients\u2019 administration preferences: progesterone vaginal insert (Endometrin(R)) compared to intramuscular progesterone for Luteal phase support. Reprod Health. 2014;11:78. https:\/\/doi.org\/10.1186\/1742-4755-11-78.","journal-title":"Reprod Health"},{"issue":"5","key":"2158_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/09513590.2020.1727879","volume":"36","author":"AM Abdelhakim","year":"2020","unstructured":"Abdelhakim AM, Abd-ElGawad M, Hussein RS, Abbas AM. Vaginal versus intramuscular progesterone for luteal phase support in assisted reproductive techniques: a systematic review and meta-analysis of randomized controlled trials. Gynecol Endocrinol. 2020;36(5):389\u201397. https:\/\/doi.org\/10.1080\/09513590.2020.1727879.","journal-title":"Gynecol Endocrinol"},{"issue":"11","key":"2158_CR6","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1210\/jc.2013-3937","volume":"99","author":"RJ Paulson","year":"2014","unstructured":"Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014;99(11):4241\u20139. https:\/\/doi.org\/10.1210\/jc.2013-3937.","journal-title":"J Clin Endocrinol Metab"},{"key":"2158_CR7","unstructured":"Data on file. Ferring Pharmaceuticals Inc.; 2019."},{"key":"2158_CR8","unstructured":"Crinone. Prescribing information. Watson Pharma Inc.\/Actavis Pharma; 2013."},{"key":"2158_CR9","unstructured":"Endometrin. Prescribing information. Ferring Pharmaceuticals, Inc.; 2018."},{"key":"2158_CR10","unstructured":"Milprosa. Prescribing information. Ferring Pharmaceuticals, Inc.; 2020."},{"issue":"6","key":"2158_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.fertnstert.2012.12.052","volume":"99","author":"L Stadtmauer","year":"2013","unstructured":"Stadtmauer L, Silverberg KM, Ginsburg ES, Weiss H, Howard B. Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertil Steril. 2013;99(6):1543\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.12.052.","journal-title":"Fertil Steril"},{"issue":"6","key":"2158_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.fertnstert.2018.07.014","volume":"110","author":"ES Ginsburg","year":"2018","unstructured":"Ginsburg ES, Jellerette-Nolan T, Daftary G, Du Y, Silverberg KM. Patient experience in a randomized trial of a weekly progesterone vaginal ring versus a daily progesterone gel for luteal support after in vitro fertilization. Fertil Steril. 2018;110(6):1101\u2013e83. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.07.014.","journal-title":"Fertil Steril"},{"issue":"4","key":"2158_CR13","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.fertnstert.2017.02.107","volume":"107","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2017","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Guidance on the limits to the number of embryos to transfer: a committee opinion. Fertil Steril. 2017;107(4):901\u20133. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.02.107.","journal-title":"Fertil Steril"},{"key":"2158_CR14","doi-asserted-by":"publisher","unstructured":"Golan A, Weissman A, Symposium. Update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009;19(1):28\u201332. https:\/\/doi.org\/10.1016\/s1472-6483(10)60042-9","DOI":"10.1016\/s1472-6483(10)60042-9"},{"issue":"1","key":"2158_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0015-0282(01)01847-7","volume":"76","author":"KM Wyatt","year":"2001","unstructured":"Wyatt KM, Dimmock PW, Walker TJ, O\u2019Brien PM. Determination of total menstrual blood loss. Fertil Steril. 2001;76(1):125\u201331. https:\/\/doi.org\/10.1016\/s0015-0282(01)01847-7.","journal-title":"Fertil Steril"},{"issue":"1","key":"2158_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/jog.12124","volume":"40","author":"I Esinler","year":"2014","unstructured":"Esinler I, Bozdag G, Karakoc Sokmensuer L. Mandatory single embryo transfer policy dramatically decreases multiple pregnancy rates. J Obstet Gynaecol Res. 2014;40(1):75\u20139. https:\/\/doi.org\/10.1111\/jog.12124.","journal-title":"J Obstet Gynaecol Res"},{"issue":"8","key":"2158_CR17","doi-asserted-by":"publisher","first-page":"Cd003416","DOI":"10.1002\/14651858.CD003416.pub5","volume":"8","author":"MS Kamath","year":"2020","unstructured":"Kamath MS, Mascarenhas M, Kirubakaran R, Bhattacharya S. Number of embryos for transfer following in vitro fertilisation or intra-cytoplasmic sperm injection. Cochrane Database Syst Rev. 2020;8(8):Cd003416. https:\/\/doi.org\/10.1002\/14651858.CD003416.pub5.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2158_CR18","doi-asserted-by":"publisher","first-page":"Cd002118","DOI":"10.1002\/14651858.CD002118.pub6","volume":"5","author":"D Glujovsky","year":"2022","unstructured":"Glujovsky D, Quinteiro Retamar AM, Alvarez Sedo CR, Ciapponi A, Cornelisse S, Blake D. Cleavage-stage versus blastocyst-stage embryo transfer in assisted reproductive technology. Cochrane Database Syst Rev. 2022;5(5):Cd002118. https:\/\/doi.org\/10.1002\/14651858.CD002118.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2158_CR19","doi-asserted-by":"publisher","first-page":"105206","DOI":"10.1016\/j.rbmo.2025.105206","volume":"52","author":"G Griesinger","year":"2026","unstructured":"Griesinger G, Wang Q, Labarta E, et al. Network meta-analysis of progestogen administration routes for luteal phase support in fresh embryo transfer IVF cycles. Reprod Biomed Online. 2026;52(2):105206. https:\/\/doi.org\/10.1016\/j.rbmo.2025.105206.","journal-title":"Reprod Biomed Online"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02158-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T13:39:13Z","timestamp":1780061953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02158-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":19,"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02158-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.S., V.S., J.P., and C.S. were investigators in the SARA trial. P.H. and E.F. were employees of Ferring Pharmaceuticals, Inc. during the design, conduct, and analysis of the SARA trial. S.G. is a full-time employee of Ferring Pharmaceuticals A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}